[Postoperative antithrombotic treatment in diabetic patients]

Area of Science:

• Cardiology
• Diabetology
• Pharmacology

Background:

• Patients with diabetes mellitus after aorto-coronary bypass (CABG) surgery are at significantly increased risk for secondary coronary events.
• Current secondary prevention strategies for these patients are extrapolated from general coronary artery disease (CAD) cohorts, lacking specific data for this population.
• Diabetic patients post-myocardial infarction (MI) represent a particularly high-risk subgroup requiring tailored therapeutic approaches.

Purpose of the Study:

• To address the specific needs of secondary prevention in diabetic patients post-CABG.
• To evaluate the efficacy and applicability of antiplatelet and antithrombotic agents in this cohort.
• To provide evidence-based recommendations for optimizing secondary prevention strategies.

Main Methods:

• Review of existing literature and clinical guidelines on secondary prevention in CAD and diabetes.
• Analysis of risk stratification and therapeutic options, including dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC).
• Consideration of specific patient subgroups, such as those post-MI or with reduced ejection fraction (EF).

Main Results:

• Combined therapy with clopidogrel and aspirin (ASS) is a viable option for secondary prevention, even in resource-limited settings.
• Oral anticoagulation with coumadin is an effective alternative to DAPT.
• OACs should be considered more liberally in specific conditions like ventricular aneurysms, EF < 30%, or certain coronary anatomies.

Conclusions:

• Diabetic patients post-CABG require specialized secondary prevention strategies.
• Combination antiplatelet therapy or oral anticoagulation offers effective risk reduction for secondary coronary events.
• Individualized treatment decisions, considering patient-specific factors, are crucial for optimal outcomes.